Jazz Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 2/6
Jazz Pharmaceuticals has a total shareholder equity of $4.2B and total debt of $6.1B, which brings its debt-to-equity ratio to 146.6%. Its total assets and total liabilities are $12.3B and $8.1B respectively. Jazz Pharmaceuticals's EBIT is $867.6M making its interest coverage ratio 3.4. It has cash and short-term investments of $2.6B.
Key information
146.6%
Debt to equity ratio
US$6.11b
Debt
| Interest coverage ratio | 3.4x |
| Cash | US$2.62b |
| Equity | US$4.17b |
| Total liabilities | US$8.08b |
| Total assets | US$12.26b |
Recent financial health updates
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?
Oct 22
Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden
Jun 23Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?
Feb 18Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly
Oct 31Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?
Jul 12We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt
Apr 12Recent updates
Jazz Pharmaceuticals: High Uncertainty, Low Risk
Nov 18We Think Jazz Pharmaceuticals' (NASDAQ:JAZZ) Profit Is Only A Baseline For What They Can Achieve
Nov 14Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?
Oct 22Jazz Pharmaceuticals: Unexpected Wins Improve The Long-Term Outlook
Oct 16Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Looks Inexpensive But Perhaps Not Attractive Enough
Sep 25Jazz Pharmaceuticals: Zanidatamab Is A Potential Growth Catalyst
Sep 19Here's Why Shareholders Should Examine Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) CEO Compensation Package More Closely
Jul 18Here's Why Jazz Pharmaceuticals (NASDAQ:JAZZ) Has A Meaningful Debt Burden
Jun 23Jazz Pharmaceuticals: Pipeline Setback While Business Transition Continues
Jun 21Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
Apr 15Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price
Apr 02Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?
Feb 18Updated View On Jazz Pharmaceuticals' 2025 Goals
Jan 29Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking
Dec 26Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly
Oct 31Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?
Jul 12We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt
Apr 12Financial Position Analysis
Short Term Liabilities: JAZZ's short term assets ($4.4B) exceed its short term liabilities ($1.0B).
Long Term Liabilities: JAZZ's short term assets ($4.4B) do not cover its long term liabilities ($7.1B).
Debt to Equity History and Analysis
Debt Level: JAZZ's net debt to equity ratio (83.8%) is considered high.
Reducing Debt: JAZZ's debt to equity ratio has increased from 52.6% to 146.6% over the past 5 years.
Debt Coverage: JAZZ's debt is not well covered by operating cash flow (19%).
Interest Coverage: JAZZ's interest payments on its debt are well covered by EBIT (3.4x coverage).